Enanta

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Enanta and other ETFs, options, and stocks.

About ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. 

CEO
Jay R. Luly
CEOJay R. Luly
Employees
120
Employees120
Headquarters
Watertown, Massachusetts
HeadquartersWatertown, Massachusetts
Founded
1995
Founded1995
Employees
120
Employees120

ENTA Key Statistics

Market cap
383.00M
Market cap383.00M
Price-Earnings ratio
-5.46
Price-Earnings ratio-5.46
Dividend yield
Dividend yield
Average volume
183.52K
Average volume183.52K
High today
$13.38
High today$13.38
Low today
$12.97
Low today$12.97
Open price
$13.38
Open price$13.38
Volume
173.40K
Volume173.40K
52 Week high
$17.15
52 Week high$17.15
52 Week low
$7.05
52 Week low$7.05

Stock Snapshot

As of today, Enanta(ENTA) shares are valued at $13.16. The company's market cap stands at 383M, with a P/E ratio of -5.46.

On 2026-08-16, Enanta(ENTA) stock traded between a low of $12.97 and a high of $13.38. Shares are currently priced at $13.16, which is +1.5% above the low and -1.6% below the high.

The Enanta(ENTA)'s current trading volume is 173.4K, compared to an average daily volume of 183.52K.

In the last year, Enanta(ENTA) shares hit a 52-week high of $17.15 and a 52-week low of $7.05.

In the last year, Enanta(ENTA) shares hit a 52-week high of $17.15 and a 52-week low of $7.05.

ENTA News

TipRanks 4d
Enanta Pharmaceuticals Flags Ongoing Uncertainty as 2025 Risk Factors Continue to Shape 2026 Outlook

Enanta Pharmaceuticals (ENTA) has disclosed a new risk, in the Regulation category. Unlock powerful investing tools with TipRanks Premium to make smarter, more...

Simply Wall St 5d
Enanta Pharmaceuticals Stock Faces Revenue Slip And Wider Losses - simplywall.st

...

Enanta Pharmaceuticals Stock Faces Revenue Slip And Wider Losses - simplywall.st
TipRanks 6d
Enanta reports Q3 EPS (67c), consensus (51c)

Reports Q3 revenue $14.4M, consensus $16.8M. “During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly,...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ENTA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.